Connect Biopharma to Present Groundbreaking Research at EAACI

Author: Dominic Sanders Updated: 06-03-2025 09:04 AM

Connect Biopharma's Innovative Presentations at EAACI 2025

Connect Biopharma Holdings Limited (NASDAQ: CNTB), a pioneering clinical-stage biopharmaceutical company focused on enhancing care for asthma and chronic obstructive pulmonary disease (COPD), is making waves in the medical community. The company recently announced its plans to present two significant oral presentations at the upcoming European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress.

Presentation Details

The EAACI Congress is set to take place from June 13 to June 16, 2025, with sessions occurring both in Glasgow and online. Connect Biopharma will present groundbreaking new research aimed at improving treatment outcomes for individuals suffering from eosinophilic driven, type 2 asthma.

First Presentation: Exacerbation Reduction

The first abstract, titled Reduction in Annualized Exacerbations with Rademikibart in Eosinophilic Driven, Type 2 Asthma, will be presented by Dr. Rekha Chaudhuri. This presentation, listed under Abstract Number 001671, is part of the Clinical Trials on Airways Diseases session and is scheduled for Friday, June 13th, from 3:00 p.m. to 4:30 p.m. BST.

Second Presentation: Lung Function Improvement

The second presentation, Improvement in Lung Function with Rademikibart in Eosinophilic Driven, Type 2 Asthma, shares the same presenter and session details as the first. Its Abstract Number is 001678, and it aims to showcase the positive impact of Rademikibart on lung function in asthma patients during the same session.

Significance of Rademikibart

Rademikibart represents a next-generation solution aimed at addressing acute asthma exacerbations, a significant concern for many patients and healthcare providers alike. The need for effective treatment options is paramount, with roughly 1 million asthma patients and 1.3 million COPD patients in the U.S. experiencing acute exacerbations every year.

In prior clinical trials, Rademikibart has shown promising results with notable reductions in exacerbation rates and rapid improvements in forced expiratory volume in one second (FEV₁), with effects observable within as little as 24 hours. These findings underscore the potential benefits of this innovative treatment for those grappling with asthma and COPD.

Company Overview

Connect Biopharma is committed to transforming the landscape of care for patients suffering from asthma and COPD. Based in San Diego, the company is dedicated to advancing therapies that not only address the acute needs of patients but also enhance their overall quality of life.

To learn more about Connect Biopharma and their groundbreaking initiatives, you can visit www.connectbiopharm.com.

Contact Information

Investor Relations Contact:

Alex Lobo
Precision AQ
Alex.lobo@precisionaq.com
(212) 698-8802

Media Contact:

Ignacio Guerrero-Ros, Ph.D., or David Schull
Russo Partners, LLC
Ignacio.guerrero-ros@russopartnersllc.com
(858) 717-2310 or (646) 942-5604

Frequently Asked Questions

What is the significance of the oral presentations by Connect Biopharma?

The presentations will highlight groundbreaking research on Rademikibart's effects on asthma and COPD, showcasing its efficacy in reducing exacerbations.

Who is presenting the findings at the EAACI Congress?

Dr. Rekha Chaudhuri is the presenter for Connect Biopharma's oral presentations.

When are the presentations scheduled?

The presentations are set for June 13, 2025, during the EAACI Congress in Glasgow and online.

What is Rademikibart?

Rademikibart is a next-generation anti-interleukin-4-receptor alpha (IL-4R?) antibody being developed to treat asthma and COPD effectively.

Where can I find more information about Connect Biopharma?

You can explore more about the company and its innovative approaches by visiting www.connectbiopharm.com.

About The Author

Dominic Sanders here, a writer and financial specialist committed to helping my readers understand the world of finance. Having a strong financial background and a lot of experience, I concentrate on using my blog posts and articles to translate difficult financial subjects into understandable, doable advice. My goal in writing is to arm you with the information and skills need to make wise financial choices.

Writing for several financial blogs has let me interact with a wide range of readers, from novice investors seeking new perspectives to seasoned investors. My mission is to make money understandable and approachable so you may confidently take charge of your financial future. I appreciate you walking this road with me to success and financial literacy.

Contact Dominic Sanders privately here. Or send an email with ATTN: Dominic Sanders as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.